Literature DB >> 21750524

Multiple sclerosis: Cladribine--a contentious therapeutic contender for MS.

Reinhard Hohlfeld.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21750524     DOI： 10.1038/nrneurol.2011.105

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN： 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  5 in total

Review 1.  Oral therapies for multiple sclerosis: a review of agents in phase III development or recently approved.

Authors:  Ralf Gold
Journal:  CNS Drugs       Date:  2011-01       Impact factor: 5.749

2.  Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis.

Authors:  Gavin Giovannoni; Stuart Cook; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Anthony Hamlett; Vissia Viglietta; Steven Greenberg
Journal:  Lancet Neurol       Date:  2011-04       Impact factor: 44.182

3.  A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis.

Authors:  Gavin Giovannoni; Giancarlo Comi; Stuart Cook; Kottil Rammohan; Peter Rieckmann; Per Soelberg Sørensen; Patrick Vermersch; Peter Chang; Anthony Hamlett; Bruno Musch; Steven J Greenberg
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

4.  A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

Authors:  Ludwig Kappos; Ernst-Wilhelm Radue; Paul O'Connor; Chris Polman; Reinhard Hohlfeld; Peter Calabresi; Krzysztof Selmaj; Catherine Agoropoulou; Malgorzata Leyk; Lixin Zhang-Auberson; Pascale Burtin
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245

5.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

Authors:  Jeffrey A Cohen; Frederik Barkhof; Giancarlo Comi; Hans-Peter Hartung; Bhupendra O Khatri; Xavier Montalban; Jean Pelletier; Ruggero Capra; Paolo Gallo; Guillermo Izquierdo; Klaus Tiel-Wilck; Ana de Vera; James Jin; Tracy Stites; Stacy Wu; Shreeram Aradhye; Ludwig Kappos
Journal:  N Engl J Med       Date:  2010-01-20       Impact factor: 91.245
  5 in total
  2 in total

Review 1.  Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis.

Authors:  Shyi-Jou Chen; Yen-Ling Wang; Hueng-Chuen Fan; Wen-Tsung Lo; Chih-Chien Wang; Huey-Kang Sytwu
Journal:  Clin Dev Immunol       Date:  2011-12-06

Review 2.  Multiple sclerosis: the role of cytokines in pathogenesis and in therapies.

Authors:  Amedeo Amedei; Domenico Prisco; Mario Milco D'Elios
Journal:  Int J Mol Sci       Date:  2012-10-19       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.